Back

SARS-CoV-2 BA.4 infection triggers more cross-reactive neutralizing antibodies than BA.1

Richardson, S.; Motlou, T.; van der Mescht, M.; Lambson, B.; Everatt, J.; Amoako, D.; Van Gottberg, A.; Wolter, N.; de Beer, Z.; Roma de Villiers, T.; Bodenstein, A.; van den Berg, G.; Rossouw, T. M.; Boswell, M.; Ueckermann, V.; Bhiman, J.; Moore, P.

2022-07-15 immunology
10.1101/2022.07.14.500039 bioRxiv
Show abstract

SARS-CoV-2 variants of concern (VOCs) differentially trigger neutralizing antibodies with variable cross-neutralizing capacity. Here we show that unlike SARS-CoV-2 Omicron BA.1, which triggered neutralizing antibodies with limited cross-reactivity, BA.4/5 infection triggers highly cross-reactive neutralizing antibodies. Cross-reactivity was observed both in the absence of prior vaccination and also in breakthrough infections following vaccination. This suggests that next-generation vaccines incorporating BA.4, which is spreading globally, might result in enhanced neutralization breadth.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.